Diffuse Large B-cell Lymphoma Prognosis (NCCN-IPI)

Estimate prognosis in diffuse large B-cell lymphoma

The global unit selector only affects unanswered questions
1.Age
2.Performance Status
3.LDH
4.Extranodal Sites
5.Stage
Created by

1. Age

Created by
0/5 completed

About this Calculator

The original International Prognostic Index (IPI) was developed and validated prior to the addition of rituximab to curative anthracycline-based chemotherapy.

Clinical trials have confirmed that rituximab improves the survival of individuals with diffuse large B-cell lymphoma. Using a database of patients treated in the rituximab era (the National Comprehensive Cancer Network database consisting of 1935 patients), this enhanced IPI score is able to discriminate individuals based on 5 clinical predictors (and an 8 point scoring system).

The final score is able to differentiate patients into four distinct prognostic groups for overall survival (low, low-intermediate, high-intermediate, and high risk).

The original IPI was developed by Shipp et al.

The enhanced NCCN-IPI offers improved discrimination for the overall survival of low- and high-risk patients in the rituximab era.

References

Shipp et al.

A predictive model for aggressive non-Hodgkin’s lymphoma.

New England Journal of Medicine 1993 September 30, 329 (14): 987-94

Legal Notices and Disclaimer

© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.